Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Kidney Int. 2022 Oct;102(4):930-935. doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Kidney Injury* / chemically induced
  • Acute Kidney Injury* / diagnosis
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols
  • Humans
  • Lung Neoplasms* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • pembrolizumab